Amendment No. 2 to the Manufacture and Supply Agreement, dated December 13, 2023 entered into by and between Savara ApS GEMABIOTECH SAU

AMENDMENT No. 2 TO

MANUFACTURE AND SUPPLY AGREEMENT

This Amendment No. 2 to the Manufacture and Supply Agreement (“Amendment No. 2”), dated December 13, 2023 (“Effective Date”), is entered into by and between Savara ApS, a Denmark private limited company having registered offices at c/o Lundgrens Advokatpartnerselskab, Tuborg Boulevard 12, 2900 Hellerup, Denmark (“Savara”) and GEMABIOTECH SAU, a corporation organized under the laws of Argentina, having registered offices at Fray Justo Sarmiento 2350 Edificio 2B Piso 5, Olivos, Province of Buenos Aires, Argentina (“GEMA”) (each referred herein by name, or individually, as a “Party” or collectively, as the “Parties”).

WHEREAS, Savara and GEMA entered into a Master Services Agreement dated April 26, 2019 (the “Agreement”) providing for Savara to engage GEMA to manufacture the API (as defined in the Agreement) and GEMA to achieve commercial compliance and manufacture and supply the API, which was subsequently amended by Amendment No. 1 dated December 7, 2022; and

WHEREAS, the parties now wish to amend the Agreement to modify certain terms of the Agreement.

NOW THEREFORE, in consideration of the recitals set forth above, the mutual covenants, terms and conditions set forth below, and other good and valuable consideration, the receipt and sufficiency of which is hereby acknowledged, the Parties agree as follows:

4.8 Purchase Requirement. For 10 years following the date of receipt of approval by a Regulatory Authority of the first Regulatory Filing for the marketing and sale of the first Product in any country, Savara will purchase from GEMA the API required for [***]% of such Product offered for sale (the “Purchase Requirement”); provided, however, the Purchase Requirement will no longer apply if (i) the price charged by GEMA is greater than [***]% more than the price charged by an alternative supplier, (ii) there is a Shortage of Supply, or (iii) GEMA at any time fails to fulfill a Purchase Order.

Savara ApS

c/o Savara Inc.

1717 Langhorne Newtown Rd.

Suite 300

Langhorne, PA 19047

Email: ***@***

Attention: Chief Financial & Administrative Officer

IN WITNESS WHEREOF, the parties have caused this Amendment No. 2 to the Agreement to be executed on the Effective Date set forth above.

Savara ApS GEMABIOTECH SAU

By: _/s/ David Lowrance____________ By: __/s/ Juan Ceriani_____________

Name: __David Lowrance ___________ Name: ___ Juan Ceriani____________

Title: Chief Financial & Administrative Officer Title: ____General Manager_________

Date: __December 18, 2023__________ Date: ____ December 19, 2023_______

Exhibit 6.1

Pricing and Milestone Schedule

Purchase Price of API:

Prior to Market Authorization: $[***] per gram of Molgramostim API

Following Market Authorization: $[***] per gram of Molgramostim API

Milestone Payments